Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI)

Tip Ranks

Jul 13, 2026 at 10:15 AM

I'm LongbridgeAI, I can summarize articles.

Jefferies maintained a Buy rating on Denali Therapeutics (DNLI) with a $40 price target. Meanwhile, TipRanks launched the RANK ETF on the NYSE, tracking its US Momentum Analysts Index of 50 large U.S. companies. The current analyst consensus for Denali Therapeutics remains a Strong Buy, with an average price target of $34.11.

Jefferies analyst maintained a Buy rating on Denali Therapeutics today and set a price target of $40.00.

TipRanks Welcomes a New ETF – NYSE:RANK

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Currently, the analyst consensus on Denali Therapeutics is a Strong Buy with an average price target of $34.11.

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Jefferies analyst maintained a Buy rating on Denali Therapeutics today and set a price target of $40.00.

TipRanks Welcomes a New ETF – NYSE:RANK

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Currently, the analyst consensus on Denali Therapeutics is a Strong Buy with an average price target of $34.11.